Tags

Type your tag names separated by a space and hit enter

Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Thromb Haemost. 2008 Mar; 99(3):539-45.TH

Abstract

We compared sulfated galactans (SGs) from two species of red algae using specific coagulation assays and experimental models of thrombosis. These polysaccharides have an identical saccharide structure and the same size chain, but with slight differences in their sulfation patterns. As a consequence of these differences, the two SGs differ in their anticoagulant and venous antithrombotic activities. SG from G. crinale exhibits procoagulant and prothrombotic effects in low doses (up to 1.0 mg/kg body weight), but in high doses (>1.0 mg/kg) this polysaccharide inhibits both venous and arterial thrombosis in rats and prolongs ex-vivo recalcification time. In contrast, SG from B. occidentalis is a very potent anticoagulant and antithrombotic compound in low doses (up to 0.5 mg/kg body weight), inhibiting venous experimental thrombosis and prolonging ex-vivo recalcification time, but these effects are reverted in high doses. Only at high doses (>1.0 mg/kg) the SG from B. occidentalis inhibits arterial thrombosis. As with heparin, SG from G. crinale does not activate factor XII, while the polysaccharide from B. occidentalis activates factor XII in high concentrations, which could account for its procoagulant effect at high doses on rats. Both SGs do not modify bleeding time in rats. These results indicate that slight differences in the proportions and/or distribution of sulfated residues along the galactan chain may be critical for the interaction between proteases, inhibitors and activators of the coagulation system, resulting in a distinct pattern in anti- and procoagulant activities and in the antithrombotic action.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Fonseca RJ
Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho and Programa de Glicobiologia, Instituto de Bioquímica Médica, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Brazil.
Oliveira SN
No affiliation info available
Melo FR
No affiliation info available
Pereira MG
No affiliation info available
Benevides NM
No affiliation info available
Mourão PA
No affiliation info available

MeSH

AnimalsAnticoagulantsBleeding TimeBlood CoagulationBlood Coagulation TestsDisease Models, AnimalDose-Response Relationship, DrugFactor XIIaFemaleFibrinolytic AgentsGalactansHemorrhageHeparinHumansMaleMolecular StructureMolecular WeightPlatelet AggregationRatsRats, WistarRhodophytaSulfatesThrombosisVenous Thrombosis

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18327402

Citation

Fonseca, Roberto J C., et al. "Slight Differences in Sulfation of Algal Galactans Account for Differences in Their Anticoagulant and Venous Antithrombotic Activities." Thrombosis and Haemostasis, vol. 99, no. 3, 2008, pp. 539-45.
Fonseca RJ, Oliveira SN, Melo FR, et al. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities. Thromb Haemost. 2008;99(3):539-45.
Fonseca, R. J., Oliveira, S. N., Melo, F. R., Pereira, M. G., Benevides, N. M., & Mourão, P. A. (2008). Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities. Thrombosis and Haemostasis, 99(3), 539-45. https://doi.org/10.1160/TH07-10-0603
Fonseca RJ, et al. Slight Differences in Sulfation of Algal Galactans Account for Differences in Their Anticoagulant and Venous Antithrombotic Activities. Thromb Haemost. 2008;99(3):539-45. PubMed PMID: 18327402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities. AU - Fonseca,Roberto J C, AU - Oliveira,Stephan-Nicollas M C G, AU - Melo,Fábio R, AU - Pereira,Maria G, AU - Benevides,Norma M B, AU - Mourão,Paulo A S, PY - 2008/3/11/pubmed PY - 2008/5/16/medline PY - 2008/3/11/entrez SP - 539 EP - 45 JF - Thrombosis and haemostasis JO - Thromb Haemost VL - 99 IS - 3 N2 - We compared sulfated galactans (SGs) from two species of red algae using specific coagulation assays and experimental models of thrombosis. These polysaccharides have an identical saccharide structure and the same size chain, but with slight differences in their sulfation patterns. As a consequence of these differences, the two SGs differ in their anticoagulant and venous antithrombotic activities. SG from G. crinale exhibits procoagulant and prothrombotic effects in low doses (up to 1.0 mg/kg body weight), but in high doses (>1.0 mg/kg) this polysaccharide inhibits both venous and arterial thrombosis in rats and prolongs ex-vivo recalcification time. In contrast, SG from B. occidentalis is a very potent anticoagulant and antithrombotic compound in low doses (up to 0.5 mg/kg body weight), inhibiting venous experimental thrombosis and prolonging ex-vivo recalcification time, but these effects are reverted in high doses. Only at high doses (>1.0 mg/kg) the SG from B. occidentalis inhibits arterial thrombosis. As with heparin, SG from G. crinale does not activate factor XII, while the polysaccharide from B. occidentalis activates factor XII in high concentrations, which could account for its procoagulant effect at high doses on rats. Both SGs do not modify bleeding time in rats. These results indicate that slight differences in the proportions and/or distribution of sulfated residues along the galactan chain may be critical for the interaction between proteases, inhibitors and activators of the coagulation system, resulting in a distinct pattern in anti- and procoagulant activities and in the antithrombotic action. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/18327402/Slight_differences_in_sulfation_of_algal_galactans_account_for_differences_in_their_anticoagulant_and_venous_antithrombotic_activities_ DB - PRIME DP - Unbound Medicine ER -